AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05335057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Close Other
Description: Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
Study NCT05949385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
Study NCT05065541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-3168
Description: Specified dose on specified days
Study NCT06323525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
Study NCT06323525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
Study NCT06055712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Intravenous dose(s).
Study NCT06055712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Five days oral.
Study NCT06650930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate
Description: All participants receive a single, open-label dose of oral calcium carbonate 3000mg
Study NCT05997979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 8% patch
Description: Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
Study NCT05997979 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocolloid dressing
Description: Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
Study NCT05355805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT05355805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT06617065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.
Description: The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio.
Study NCT05518110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg of Trametinib (orally) daily.
Study NCT05518110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
Study NCT06622408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HypnoVR© virtual reality headset
Description: Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
Study NCT06683534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin (dietary supplement)
Description: Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
Study NCT06683534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Study NCT06629285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous compression cryotherapy
Description: Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
Study NCT06629285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ice treatment
Description: Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
Study NCT06629077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
Study NCT06629077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: A dose of prazosin will be administered based on body weight.
Study NCT06629077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo
Study NCT06711354 — intervention group
Intervention type: DRUG
Intervention: Anti-CD20 Monoclonal Antibody
Description: Injection of monoclonal anti-CD20 antibody as immunomodulatory treatment of multiple sclerosis
Study NCT06712524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast-conserving plastic surgery
Description: The commonly used breast conserving plastic surgery includes tennis racket, bat wing, V/J breast plasty, Grisotti and so on.
Study NCT06712524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional breast surgery
Description: Traditional breast surgery
Study NCT06711718 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview (patients)
Description: Qualitative interviews to be carried out by an experienced researcher with patients who have had their diabetes diagnosis reviewed as a result of the running of the tool.
Study NCT06711718 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview (staff)
Description: Qualitative interviews to be carried out by an experienced researcher with practice staff who have run the tool and reviewed patients flagged by the tool.
Study NCT06712823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atumelnant (CRN04894)
Description: Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
Study NCT06712407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TARPEYO®
Description: 6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.
Study NCT06711081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser device cryotherapy
Description: using new device direct on the pulp tissue
Study NCT06711250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: khoury technique
Description: autogenous bone augmentation
Study NCT06711250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: khoury technique with i-PRF injections
Description: autogenous bone augmentation with repeated i-PRF injections
Study NCT06711913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine given in form of 100ml infusion over 10 minutes
Study NCT06711913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: control group receive normal saline as placebo
Study NCT06712368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: Designed cardiac physical therapy program applied through virtual reality glasses for study group
Study NCT06712368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Designed cardiac physical therapy program
Description: Designed cardiac physical therapy program without virtual reality glasses
Study NCT06421597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisoline 25 mg/day for seven days
Study NCT06421597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for seven days
Study NCT06044649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT endorses a pain management model and teaches people skills to cope with chronic pain.
Study NCT06044649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
Study NCT06044649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
Study NCT06044649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
Study NCT03952481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
Study NCT05897788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message Check-ins
Description: Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
Study NCT05897788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
Study NCT05943938 — intervention group
Intervention type: OTHER
Intervention: Epic Sepsis Model Version - 1
Description: The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
Study NCT05943938 — intervention group
Intervention type: OTHER
Intervention: Epic Sepsis Model Version - 2
Description: The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
Study NCT05943938 — intervention group
Intervention type: OTHER
Intervention: Emory Sepsis Model
Description: Emory internal algorithm
Study NCT06215196 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber Supplement Group
Description: Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
Study NCT06215196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
Study NCT05825820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach Intervention (EOI) plus Care as Usual
Description: The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts.
Study NCT05328973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ELEQUIL
Description: patch placed on skin
Study NCT05511246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venous ethanol
Description: Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
Study NCT05511246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Endocardial catheter ablation of VT substrate
Study NCT05511246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Endocardial catheter ablation of VT substrate
Study NCT06233539 — intervention group
Intervention type: OTHER
Intervention: Observational research without intervention
Description: Observational research without intervention
Study NCT04118868 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab administered using the Sofusa® DoseConnect™
Description: pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
Study NCT06516822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI only
Description: After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
Study NCT05496998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid™ TMVR TF System
Description: Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
Study NCT05062148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Float-REST
Description: Subjects receiving Float-REST will float for 60 minutes three times a week.
Study NCT05062148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
Study NCT04736758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 tablet
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: CD20xCD3 bispecific antibody
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: CD-19-directed antibody-drug conjugate
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Modified R-ICE chemotherapy
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Modified R-ICE chemotherapy
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Modified R-ICE chemotherapy
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Modified R-ICE chemotherapy
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Modified R-ICE (Treatment Arm II)
Study NCT05991388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Modified R-ICE chemotherapy
Study NCT05991388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cells (TBC)
Description: Modified R-ICE chemotherapy
Study NCT04763928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax+Decitabine
Description: Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes.
Study NCT04968847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemaSeed Localized Directional Insemination
Description: Subjects undergoing FemaSeed Artificial Insemination
Study NCT06479564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: free weight training and machine training
Description: 20 participants will be in control group who will only perform free weight and machine training
Study NCT06479564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: 20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
Study NCT04844099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin Piperaquine
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
Study NCT04844099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin Piperaquine
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
Study NCT04701060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
Description: preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Study NCT06249789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
Study NCT05380310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active SMART ANGEL solution
Description: Nurse intervention according to the alert level + traditional monitoring
Study NCT05380310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SMART ANGEL solution
Description: No alert + traditional monitoring + alert in case of imminent life threat
Study NCT06249789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
Study NCT04736758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study NCT05348330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic intervertebral foramen block
Description: Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
Study NCT05348330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-point to pleura transverse process block
Description: Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
Study NCT05646511 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SCRT
Description: 5x5 Gy: 25 Gy
Study NCT05646511 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCRT
Description: 5x5 Gy: 25 Gy
Study NCT05646511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX
Description: Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks